Home › Genzyme And Isis Announce FDA Approval Of KYNAMRO (Mipomersen Sodium) Injection For The Treatment Of Homozygous Familial Hypercholesterolemia
 

Keywords :   


Genzyme And Isis Announce FDA Approval Of KYNAMRO (Mipomersen Sodium) Injection For The Treatment Of Homozygous Familial Hypercholesterolemia

2013-01-29 19:30:00| drugdiscoveryonline News Articles

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for KYNAMRO (mipomersen sodium) injection

Tags: treatment approval injection announce

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
24.11STEINBACH40
24.11 Sepua Crue F-170
24.11 SECRET
24.11CRAwith
24.1111/15)&&
24.11 8
24.11
24.11F2023 23
More »